期刊文献+

超临界CO_2抗溶剂法制备头孢呋辛酯微粒的工艺研究 被引量:2

Preparation of cefuroxime axetil particles by supercritical CO_2 antisolvent technology
下载PDF
导出
摘要 采用超临界CO2抗溶剂法制备头孢呋辛酯微粒,以体积平均粒径为主要评价指标,在单因素实验的基础上设计正交试验优选制备头孢呋辛酯微粒的工艺,并对优选工艺组合进行粒度分布、扫描电镜、红外吸收光谱法(IR)及差示扫描热量法(DSC)的表征。正交试验得到的优选工艺为:结晶压力10 MPa,结晶温度50℃,头孢呋辛酯质量浓度6 mg/mL。在此工艺下制得的微粒体积平均粒径为6.729μm,IR与DSC分析表明头孢呋辛酯微粒的化学结构没有发生变化,热力学性质发生了变化,经过处理的头孢呋辛酯变为无定型。 Cefuroxime axetil micro particles were prepared by using supercritical CO2 anti-solvent technology. With volume average particle size as the main evaluation, on the basis of single factor experiments orthogonal experimental design was used to optimize the preparation process of cefuroxime axetil particles. The experiments such as particle size distribution, scanning electro microscope analysis ( SEMA), infrared spectrum (IR) and dif- ferential scanning calorimetry (DSC) were used to analyze the particles. The orthogonal experimental optimization process conditions were set as follows: crystallization pressure 10 MPa, crystallization temperature 50℃ and mass concentration of cefuroxime axetil 6 mg/mL, Under the optimum conditions, the volume average particle size was 6. 729μm, IR and DSC analysis showed that the chemical structure didn't change but the thermodynamic proper- ties of eefuroxime axetil might transfer transform to amorphous.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2013年第6期596-599,共4页 Journal of China Pharmaceutical University
基金 江苏省自然科学基金资助项目(No.BK2012763) 中央高校基本科研业务费专项资金资助项目(No.JKY2011026)~~
关键词 超临界CO2抗溶剂法 头孢呋辛酯 微粒 体积平均粒径 upercritical anti-solvent cefuroxime axetil particles volume average particle size
  • 相关文献

参考文献3

二级参考文献47

  • 1Bahrami, M. & Ranjbarian, S. (2007). Production of micro-and nano-composite particles by supercritical carbon dioxide.Journal of Supercritical Fluids, 40, 263-283. 被引量:1
  • 2Beach, S., Latham, D., Sidgwick, C., Hanna, M. & York, P. (1999). Control of the physical form of salmeterol xinafoate. Organic Process Research and Development, 3, 370-376. 被引量:1
  • 3Bensinger, W. (2007). Initial therapy of multiple myeloma in patients who are candidates for stem cell transplantation. Current Treatment Options in Oncology, 8(2), 135-143. 被引量:1
  • 4Bleich, J., Kleinebudde, P. & Mueller, B. W. (1994). Influence of gas density and pressure on microparticles produced with the ASES process. International Journal of Pharmaceutics, 106(1 ), 77-84. 被引量:1
  • 5Caira, M. R., Botha, S. A. & Flanagan, D. R. (1994). Polymorphism of n-(2,6-dioxo- 3-piperidyl)phthalimide(thalidomide)-Structural characterization of a second monoclinic racemic modification. The Journal of Chemical Crystallography, 24, 95-99. 被引量:1
  • 6Candoni, A., Raza, A., Galili, N., Simeone, E., Buttignol, S., Silvestri, F., et al. (2007). Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS). Leukemia Research, 31(Suppl. 1 ), 119. 被引量:1
  • 7Carini, J. P., Pavei, C., Silva, A. P. C., Machado, G., Mexias, A. S., Pereira, V. P., et al. (2009). Solid state evaluation of some thalidomide raw materials. International Journal of Pharmaceutics, 372, 17-23. 被引量:1
  • 8Chattopadhyay, P. & Gupta, R. B. (2001). Production of griseofulvin nanoparticles using supercritical CO2 antisolvent with enhanced mass transfer. International Journal of Pharmaceutics, 228, 19-31. 被引量:1
  • 9Chattopadhyay, P. & Gupta, R. B. (2002). Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChEJoumal, 48, 235-244. 被引量:1
  • 10Cipriani, P. & Smith, C. Y. (2007). Characterization of thalidomide using Raman spectroscopy. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 69(2), 333-337. 被引量:1

共引文献14

同被引文献13

  • 1Shehzad A, Ha T, Subhan F, et at. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases[J]. Eur J Nutr, 2011,50(3): 151. 被引量:1
  • 2Li Y, Zhang T. Targeting cancer stem ceils by curcumin and clinical applications[J]. Cancer Lett, 2014, 346(2) : 197. 被引量:1
  • 3Schaffer M, Sehaffer P M, Zidan J, et at. Curcuma as a func- tional food in the control of cancer and inflammation [ J]. Curt Opin Clin Nutr, 2011, 14(6) : 588. 被引量:1
  • 4A Montes, N Kin, M D Gordillo, et al. Polymer-naproxen pre- cipitation by supercritical anti-solvent (SAS) process [ J ]. J Su- percrit Fluid, 2014, 89:58. 被引量:1
  • 5Wang W, Liu G, Wu J, et ak Co-precipitation of 10-hydroxy- camptothecin and poly (L-lactic acid) by supercritical CO2 anti- solvent process using dichloromethane/ethanol co-solvent [ J ]. J Supercrit Fluid, 2013, 74: 137. 被引量:1
  • 6A Montes, M D Gordillo, C Pereyra, et at. Polymer and ampicil- lin co-precipitation by supererltical anti-solvent process [J] . J Supercrit Fluid, 2012, 63:92. 被引量:1
  • 7Zhang Y Z, Liao X M, Yin G F, et al. Preparation of water solu- ble drugs-loaded microparticles using modified solution enhanced dispersion by supercritical C02 [ J ] . Powder Technol, 2012, 221 : 343. 被引量:1
  • 8Zahihi F, Xin N, Li S, et al. Polymeric coating of fluidizing via anti-solvent supereritical method for sustained release[ J ]. J Supercrit Fluid, 2014,89 (1): 99. 被引量:1
  • 9N Suwannateep, S Wanichwecharungruang, S F Haag, et al. En- capsulated curcumin results in prolonged curcumin activity in vitro and radical scavenging activity ex vivo on skin after UVB-ir- radiation[ J]. Eur J Pharm Biopharm, 2012,82:485. 被引量:1
  • 10Zhang J, Tang Q, Xu X, et al. Development and evaluation of a novel phytosome-loaded chitosan mierosphere system for curcumin delivery[J]. Int J Pharm, 2013, 448(1) :168. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部